What does Morphic do?

Morphic Therapeutic is a clinical-stage biopharmaceutical company based in the U.S. that focuses on developing oral integrin therapies for serious chronic diseases, including autoimmune diseases, inflammatory bowel disease (IBD), pulmonary hypertensive diseases, and fibrotic diseases. It operates as a wholly owned subsidiary of Eli Lilly and Company, following a significant acquisition in July 2024. The company utilizes its proprietary MInT (Morphic Integrin Technology) Platform to create a new generation of oral integrin drugs. This platform allows for precise control of integrin proteins, which are essential for cell functions. Morphic has a library of over 16,000 unique compounds to design innovative drugs aimed at addressing current and emerging health challenges. Its lead product candidate, MORF-057, is a selective oral small-molecule inhibitor of the α4β7 integrin and is currently advancing through clinical trials for IBD, with studies focused on ulcerative colitis and Crohn's disease.